U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Transparency
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: BsUFA Meeting Management
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: BsUFA Meeting Management

 

 

Subscribe to FDA-TRACK Updates

 

FDA-TRACK: Drugs
FDA-TRACK: Biologics
BsUFA Performance Dashboard User Guide
FDA-TRACK Home

Biosimilar Applications and Supplements

Procedural Notifications

Procedural Responses

Meeting
Management

The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Biosimilar User Fee Amendments of 2017 (BsUFA II), authorizes FDA to assess and collect fees for biosimilar biological products from October 2017 through September 2022. FDA dedicates these fees to expediting the review process for biosimilar biological products, facilitating the development of safe and effective biosimilar products for the American public.

Download BsUFA Meeting Management Dataset

Footnotes:

  • * Performance is currently preliminary due to pending submissions.
  • ** New Performance Goal for BsUFA II (see Changes for this Goal, pages 22-24)
Back to Top